Objective: Craving plays significant role inrelapse in patients with alcohol dependence syndrome. Baclofen and topirmateare effective in reduction of craving and maintenance of abstinence in various placebo controlled trials.

Method: It is a retrospective study of patients of alcohol dependence who were admitted in de–addiction ward from January– December 2013. Case record files of patient who completed detoxification and were prescribed either baclofen or topiramate were taken out and analyzed after applying coding plan.

Results:  A total of 68 patients fulfilled the inclusion criteria, 40 in baclofen group and 28 in topiramte group. Mean age was 38 years in baclofen group and 41 years in topiramate group. Majority of the patients in both the groups were married and employed. Majority of the patients in both the groups had duration of alcohol dependence between 5–10 years. 32.5 % patients in baclofen group did not report craving at 3 months against 14.2% in topiramte group and 47.5% patients in baclofen group remained abstinent at 3 months against 28.5% in topiramate group.

Conclusion: Both baclofen and topiramate are effective in reduction of craving and maintaining abstinence in patients with alcohol dependence syndrome and baclofen fared better than topiramate.